ZM-H1505R
Chronic Hepatitis B
Phase 1Active
Key Facts
About Zhimeng Biopharma
Clinical-stage biotech developing novel small molecules for functional cure of chronic hepatitis B and treatment of severe neurological disorders.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed CAM | Zhimeng Biopharma | Clinical |
| Undisclosed Immunomodulator | Zhimeng Biopharma | Clinical |
| Selgantolimod (GS-9688) | Gilead | Phase 2 |
| Bepirovirsen | GSK | Phase III |
| BRII-835 (VIR-2218) + BRII-179 (VBI-2601) | Brii Biosciences | Phase 2 |
| BRII-179 (VBI-2601) | Brii Biosciences | Phase 2a/2b |
| VIR-3434 | Brii Biosciences | Preclinical/Phase 1 (ex-China) |
| Collaboration with Aligos Therapeutics | Amoytop Biotech | Clinical |
| JNJ-3989 | Johnson & Johnson | Phase 2 |
| APG-1387 | Ascentage Pharma Group | Phase 2 |
| VTP-300 | Barinthus Biotherapeutics | Phase 1b/2a |